Verve Therapeutics (VERV) 101 Presentations and Data Reaffirm the Company's Best in Class Status - William Blair
Tweet Send to a Friend
William Blair analyst Raju Prasad reiterated an Outperform rating on Verve Therapeutics (NASDAQ: VERV) after the company gave two presentations ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
